Kinsella Group Brings Together Innovators and Investors to Advance MedTech
Growth capital is a key part of Kinsella Group’s offering. It leverages our focused expertise to connect MedTech investors and innovators in thoughtful ways that advance the field and accelerate growth. Below are a few perspectives on why growth capital in MedTech is especially important today.
In 2025, regulators cleared thousands of new and updated medical devices—including hundreds powered by AI and machine learning. As a matter of fact, the FDA’s 510(k) pathway alone cleared more than 1,800 medical devices in just the first seven months of 2025(1). Growth capital can play a critical role in market adoption and helping companies reach their full potential.
What’s driving the growing gap between MedTech innovation and the capital required to bring technologies to market?
MedTech companies today often face longer development timelines, complex reimbursement landscapes, and increasing expectations for clinical evidence. While early-stage venture funding fuels innovation, the transition to commercialization frequently requires additional capital aligned with operational expertise. Growth capital can help companies strengthen leadership teams, expand clinical programs, and build the infrastructure needed to scale.
How can the right kind of growth capital help MedTech companies bridge the critical stage between clinical validation and commercial scale?
For many companies, the period following regulatory clearance or pivotal clinical validation is where strategic capital becomes most valuable. Investment at this stage supports activities such as expanding sales channels, building manufacturing capacity, advancing new indications, and strengthening market access strategies—steps that ultimately determine whether promising technology becomes widely adopted in clinical practice.
How is Kinsella Group helping MedTech companies translate breakthrough science into sustainable growth?
Beyond funding, our experienced MedTech partners at Kinsella Group effectively connect opportunities with investors. We offer access to deep industry networks, first-hand leadership experience in new product development and market adoption, and a clear understanding of how to position growth—allowing us to identify the right growth capital partners and more rapidly scale market acceptance.
If you are an interested MedTech investor or innovation, please email for a confidential meeting.
Robert Kinsella
President, Kinsella Group
(1) https://warrick.net/wp-content/uploads/2025/08/fda-medical-device-approvals-report-202507.pdf
